TVT-SECUR A Pilot Study for the Treatment of Stress Urinary Incontinence

Sponsor

Ethicon, Inc. (Industry)

Overall Status

Completed

CT.gov ID

NCT00463554

Collaborator

(none)

Enrollment

Locations

Duration (Months)

Patients Per Site

0.6

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The primary objective of this study is to obtain clinical performance information on the GYNECARE TVT-SECUR* System (Tension-free Support for Incontinence) in women with stress urinary incontinence (SUI).

Condition or Disease	Intervention/Treatment	Phase
Stress Urinary Incontinence	Device: GYNECARE TVT-SECUR* System

Detailed Description

The primary variable for effectiveness is > 50% improvement on the subjective symptom Visual Analog Scale (VAS) at Visit 3/Week 5 (35 days post-surgery) to be accepted.

Study Design

Study Type:

Observational

Actual Enrollment :

72 participants

Observational Model:

Cohort

Time Perspective:

Prospective

Official Title:

An Evaluation of the GYNECARE TVT-SECUR* System (Tension-Free Support for Incontinence) for the Treatment of Stress Urinary Incontinence *Trademark

Study Start Date :

Apr 1, 2006

Actual Primary Completion Date :

Jan 1, 2007

Actual Study Completion Date :

Dec 1, 2007

Outcome Measures

Primary Outcome Measures

Clinical performance of TVT-SECUR* [Screening and Day 35]

Secondary Outcome Measures

Assessment of the results of the standing cough stress test [Screening, Week 5, Months 6 and 12]
Intra- and post-operative complications [Intraoperative, Week 5, Months 6 and 12]
Physician questionnaire results [Months 2 and 12]
Urodynamics [Screening, Week 5, Months 6 and 12 (post-operative optional)]
QoL measures [Screening, Week 5, Months 6 and 12]
Subject satisfaction. [Month 12]
Anesthesia [intraoperative]
Operative time [Intraoperative]

Eligibility Criteria

Criteria

Ages Eligible for Study:

21 Years and Older

Sexes Eligible for Study:

Female

Accepts Healthy Volunteers:

Inclusion Criteria:

Must be female with objective, demonstratable signs of SUI or stress predominant mixed incontinence and requires elective, primary surgical intervention.
Must be at least 21 years old.
Must be postmenopausal (amenorrhea) for at least 1 year or surgically sterile (bilateral salpingo-oophorectomy or tubal ligation or otherwise be incapable of pregnancy) or has a negative pregnancy test prior to study entry and has decided to cease childbearing.
Agrees to participate in the study, including all study related procedures and evaluations and documents this agreement by signing the IRB/EC-approved informed consent

Exclusion Criteria:

Have any other coexistent pathology requiring concomitant surgery that may impact this procedure i.e. surgeries that involve the anterior vaginal wall (e.g. anterior colporrhaphy, diverticula, anterior Prolift) Any allowable concomitant surgery must be performed prior to the GYNECARE TVT SECUR System surgery.
Have intrinsic sphincter deficiency (ISD) [Urethral Pressure Profile (UPP) with a maximum urethral closing pressure (MUCP) < 20cm H2O or Leak Point Pressure (LPP) < 60].
Have an active urinary tract infection (UTI) or vaginal infection at time of surgery.
Have a fixed urethra (< 30° mobility on Q-Tip Straining Test).
Have had prior incontinence surgery.
Have a post-void residual volume > 100mL.
Have co-existent pelvic organ prolapse that is symptomatic or extends beyond the hymen.
Have lower urinary tract pathology in the form of a fistula or diverticulum.
Have a malignancy or with a history of malignancy within the past 5 years, except for a basal cell carcinoma that has been treated with local excision and is no longer present.
Are on anticoagulant therapy.
Have received an experimental drug or used an experimental medical device within 30 days prior to the planned start of treatment.
Are deemed by the investigator as medically unfit for surgery or who in the opinion of the investigator should not be enrolled in the study because of the precautions, warnings or contraindications outlined in the GYNECARE TVT SECUR System IFU.
Employees of the investigator or study center with direct involvement in the proposed study or other studies under the direction of that investigator or study center.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Michigan Institute of Women's Health	Dearborn	Michigan	United States	48124
2	Good Samaritan Hospital	Cincinnati	Ohio	United States	45220-2489
3	The Institute for Female Pelvic Medicine and Reconstructive Surgery	Allentown	Pennsylvania	United States	18104
4	Vanderbilt University	Nashville	Tennessee	United States	37232
5	Helsinki University Central Hospital	Helsinki		Finland	00028
6	University of Padova	Padova		Italy	35128